Nanyang Technological University

Singapore Health Services Pte Ltd

Mayo Foundation for Medical Education and Research

Tan Tock Seng Hospital Pte Ltd

National University of Singapore

Subramanian Venkatraman

Yin Chiang Freddy Boey

Tina Wong

Jayaganesh V Natarajan

Yin Chiang Boey

Say Chye Joachim Loo

Jodhbir Singh Mehta

Yingying Huang

Tina Tzee Ling Howden

Leonardus Kresna Widjaja

John C Burnett, Jr

Horng H Chen

Weimin Huang

Chee Kai Chua

Bo Liedberg

Terry W J Steele

Jia An

Tina Howden

Nicolas Daniel Marie Foin

Laxmikant Khanolkar

Kiang Hiong Tay

Yong-dan Tang

Chee Wee Gan

Hong Duc Duong

Wei Luen James Yip

Xu Wen Ng

En Hou Philip Wong

Freddy Boey

Wei Wu

Lei Shang

Scott Alexander Irvine

Lim Soo Ghim

Yee Shan Wong

Vitali Llpik

Jodhbir Metha

Animesh Agrawal

Laximikant Khanolkar

Abhijit Vijay Salvekar

Debasish Mondal

Anthony Herr Cheun Ng

Marc Abadie

Andri Riau

Tzee Ling Tina Wong

Bjorn Neu

Hsueh Yee Lynne Lim

Prasada Rao

Hui Ying Ang

Sing Joo Chia

Wai Hon Chooi

Herr Cheun Anthony Ng

Vitali Lipik

According to the present disclosure, the use of a nanoliposome in the manufacture of a medicament for the prophylaxis and/or treatment of anterior segment ocular diseases is provided. The nanoliposome comprises a plurality of unsaturated and/or saturated lipids forming at least one lipid bilayer encapsulating a hydrophobic drug comprising tacrolimus, wherein the hydrophobic drug and the plurality of unsaturated and/or saturated lipids have a weight ratio of up to 0.2. The present disclosure also provides for such a nanoliposome and a method of preventing and/or treating anterior segment ocular diseases based on the nanoliposomes.

Nanoliposomes for sustained delivery of tacrolimus for treatment of anterior segment eye diseases

Disclosed is an optical cylinder of a corneal prosthesis comprising: a) an optical cylinder comprising a solid polymer, and b) a plurality of nanoparticles forming a substantially uniform layer on a circumference of the solid polymer surface of the optical cylinder. Also disclosed are methods of surface treatment of optical cylinders of corneal prostheses, and corneal prostheses thereof.

Optical cylinder and method of surface treatment of the same

An occlusion device for closing an anatomical defect in tissue comprising a conduit connecting an opening on a first tissue and an opening on a second tissue is provided. The occlusion device comprises a scaffold comprising a) a proximal support structure comprising at least two arms; b) a distal support structure comprising at least two arms, wherein the arms are adapted to provide anchorage for the device in the tissue; and c) a waist portion adapted for extending through the opening on the first tissue and connecting the proximal support structure with the distal support structure, wherein the scaffold consists essentially of a biodegradable polymer, wherein the proximal support structure and the distal support structure comprise or consist of polycaprolactone (PCL), poly-(D,L-lactide-co-caprolactone) (PLC), or a mixture thereof. A method of closing an anatomical defect using the occlusion device is also provided.

Occlusion device for closing anatomical defects

The present invention generally relates to the field of transcatheter device closure techniques for closing an opening in a tissue and more particularly, to occlusion devices for closing anatomical defects in tissue such as defects consisting of an opening connecting a front side and a back side of a tissue. More particularly the present invention relates to occlusion devices for closing septal abnormalities such as atrial septal defects and patent foramen ovale, delivering systems for such occlusion devices, kits comprising the occlusion devices and the delivering systems and to methods of closing an anatomical defect in a tissue consisting of an opening connecting a front side and a back side of a tissue.

According to the present disclosure, a hydrophobic polymeric composite comprising a hydrophobic polymer matrix with hydrophobically modified particles dispersed therein is provided. The hydrophobically modified particles may be derived from hydrophilic particles modified with organic moieties. The hydrophobically modified particles may also take in the form of core-shell fibers with hydrophilic particles encapsulated inside the core of said fibers or in the form of monolithic fibers embedded with hydrophilic particles. The method for making hydrophobic polymeric composite comprising each of the various hydrophobically modified particles is also provided. The hydrophobic polymer matrix can be chosen from poly(alpha-hydroxyesters), of carbonates, polyurethanes or polyalkanoates. For example, hydrophilic particles, such as barium sulphate, zirconium oxide, tantalum oxide or bismuth oxide, are dispersed in the hydrophobic biodegradable polymers, such as poly-(L-lactide) (PLLA).

Composite material with enhanced mechanical properties and a method to fabricate the same

Provided is a glaucoma valve, a casing for containing a glaucoma valve and a glaucoma drainage device including the glaucoma valve and/or the casing. The valve includes a flow channel having an inlet and an outlet and a valve member connected to the outlet of the flow channel. The valve member may be formed from a degradable polymer or a combination of degradable polymer and non-degradable polymer. The valve may have a first flow channel, the interior of which may be coated with a degradable polymer, such that in use, the polymer degrades to allow a greater flow of fluid through the flow channel. The valve may include a second flow channel, which may be arranged in parallel to the first flow channel. The casing may be formed from a degradable polymer, such as a biodegradable polymer.

Glaucoma valve, a casing for containing a glaucoma valve, and a glaucoma drainage device comprising the valve and/or the casing

According to embodiments of the present invention, an embolic device for embolizing a target vascular site is provided. The embolic device includes a biodegradable shape memory element having an original shape and a deformed shape, wherein the biodegradable shape memory element in the deformed shape is in at least one dimension of a smaller size than the biodegradable shape memory element in the original shape, and wherein the biodegradable shape memory element is provided in the deformed shape and configured to resume the original shape in response to an external stimulus being applied to the biodegradable shape memory element in its deformed shape, to embolize the target vascular site and prevent fluid flow through the target vascular site. According to further embodiments of the present invention, an apparatus for embolizing a target vascular site and a method thereof are also provided.

Embolic device, an apparatus for embolizing a target vascular site and a method thereof

The invention relates to a multilayered nanoparticle for delivery of RNA to a cell and methods of manufacturing and using the same. The multilayered nanoparticle has a core nanoparticle coated by alternating positively and negatively charged polymer layers, wherein the at least one of the negatively charged polymer layers is RNA.

Multilayered nanoparticle and methods of manufacturing and using the same

The present invention is directed to a liposomal formulation for ocular drug delivery comprising (i) liposomes comprising at least one lipid bilayer, and (ii) a prostaglandin drug and/or a prostaglandin derivative associated in the liposomes, wherein the liposomes have a mean diameter of less than 2&#x3bc;&#x3c0;&#x3b9;. The present invention is also directed to a pharmaceutical comprising the liposomal formulation and a method of producing the liposomal formulation for ocular drug delivery. Additionally, the present invention is directed to a method of treating or preventing an ocular disease, comprising administering the liposomal formulation or the pharmaceutical composition to a subject in need thereof.

Liposomal formulation for ocular drug delivery

A device and method for forming an anastomotic joint between two parts of a human or animal body having a hollow connector with at least two proximal arms biased towards an open position; and at least two distal arms biased towards an open position, wherein in use when pressure is applied to the proximal arms to overcome the bias into a position in which the proximal arms are closer to each other; similarly pressure is applied to the distal arms to overcome the bias into a position in which the distal arms are closer to each other; the distal end can be pushed into a passage in the first human or animal body part until the distal arms are located in the first lumen of the first body part and released allowing the distal arms to move to the biased position to urge against the first lumen of the first body part; and the proximal end can be pushed into a passage in the second human or animal body part until the proximal arms are located in the second lumen of the second body part and released allowing the proximal arms to move to the biased position to urge against the second lumen of the second body part.

Device and method for forming an anastomotic joint between two parts of a body

The present invention relates to novel hyaluronic acid (HA) hydrogels comprising vesicles loaded with a drug or a protein or a nucleic acid. The new HA hydrogels provide sustain release formulations that are useful for several clinical and surgical applications, including but not limited to ophthalmology (e.g. glaucoma, corneal, ocular inflammatory, vitreoretinal and medical retinal diseases) and dermatological conditions.

Hyaluronic acid-based drug delivery systems

The present invention relates to the field of non-biodegradable stents, and therein to non-biodegradable stents coated with at least one layer of a biodegradable polymer which maintains mechanical integrity of the coating both in storage and upon balloon expansion and which can optionally release drugs. The at least one polymer layer comprises a biodegradable polymer and a plasticizer. The present invention also relates to a manufacturing method of such a non-biodegradable stent.

Non-biodegradable stent comprising a biodegradable coating and method of coating the same

A stable liposomal formulation for ocular delivery. The formulation contains a liposome that includes at least one lipid bilayer containing a phosphatidylcholine, and a prostaglandin Fencapsulated in the liposome. Also provided is a method for treating an ocular disorder with the formulation.

Stable liposomal formulations for ocular drug delivery

Present invention relates to a device for controlled release of a bioactive agent. The device comprises a thin film located on the surface of the device, wherein said thin film comprises a bioactive agent-containing layer comprising a polymeric matrix and at least one bioactive agent.

Device for controlled release of a bioactive agent

Provided is a biodegradable ocular implant for sustained drug delivery, including a first layer comprising a first biodegradable polymer, wherein the first layer contains a drug dispersed or dissolved therein. A multi-layered biodegradable ocular implant is also disclosed.

Biodegradable ocular implant

Growing community of inventors

Singapore, Singapore

Subramanian Venkatraman